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doi:10.1016/j.ejvs.2011.01.010Abstract Background: In selected cases of deep vein thrombosis (DVT), catheter-directed
thrombolysis (CDT) may be superior to conventional treatment with anticoagulation alone,
as it can prevent DVT recurrence and the development of post-thrombotic syndrome (PTS).
Percutaneous mechanical thrombectomy (PMT) devices offer a minimally invasive adjunctive
strategy and the data on these emerging technologies require review.
Objectives: To review the evidence for PMT devices in DVT in terms of case selection, tech-
nical feasibility and procedural outcomes.
Methods: Medline, trial registries, conference proceedings and article reference lists
were searched to identify case series reporting PMT device use. Data were extracted for
review.
Results: 16 retrospective case series have reported the use of rheolytic, rotational, or ultra-
sound-assisted PMT in a total of 481 patients. No randomised trials were available. Technical
success of 82e100% was reported with Grade II or III lysis in 83e100% of patients. The different
devices all appeared to be safe, with no reported procedure-related deaths or strokes and <1%
incidence of symptomatic PE. Bleeding complications were reported in 6/16 studies, in which
4e14% of patients required transfusion (global incidence 11/146 patients, 7.5%).
Conclusion: PMT appears feasible and safe, though the level of evidence available is poor.
Major RCTs and registry data are required to determine the economic and clinical benefit of
various devices used alone or in combination, for differing thrombus characteristics andeducation questions on this paper, please go to www.vasculareducation.com and click on ‘CME’
Vascular Institute, Room 4.007, St George’s Healthcare NHS Trust, Blackshaw Road, London SW17 0QT,
3205; fax: þ44 (0)20 8725 3495.
P.J.E. Holt).
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Deep venous thrombosis (DVT) is a major public health
challenge, representing a significant clinical and economic
disease burden on healthcare systems. In the UK alone,
approximately 59,000 new cases of DVT arise per year1 and
venous thromboembolism (VTE) accounts for more deaths
than the composite mortality of breast cancer, AIDS and
road traffic accidents.2 Up to 21% of DVT may lead to
pulmonary embolism (PE), a potentially life-threatening
complication.3 Furthermore, DVT may cause severe
morbidity in the short-term from phlegmasia caerulea
dolens (PCD) and in the longer-term from chronic venous
hypertension leading to the post-thrombotic syndrome
(PTS).4 Up to 10% of patients with DVT develop venous
ulceration.5,6 The resulting economic burden of patients
with previous DVT is significant, costing the UK approxi-
mately £640 million per annum.2
The conventional treatment of acute DVT is immediate
anticoagulation with low molecular-weight heparin or
unfractionated heparin, followed by a period (3e6 months)
of oral anticoagulation with warfarin.7 This aims to prevent
thrombus propagation and to reduce the risks of PE and DVT
recurrence.8 However, anticoagulation does not have
significant fibrinolytic activity and patients with severe,
extensive, proximal DVTs remain at high risk of developing
subsequent PTS and potentially ulceration as demonstrated
in natural history studies.9e11 In cases of DVT treated with
anticoagulation alone, natural history studies have shown
that early spontaneous clot lysis frequently resulted in
preservation of valvular function (which intuitively might
reduce post-thrombotic morbidity).11
Evidence supporting the benefit of early clot removal
has largely been acquired after open thrombectomy;
a Scandinavian randomized controlled trial reported
improved patency, lower venous pressures, less oedema
and fewer post-thrombotic symptoms at 10 years’ follow-up
in patients randomised to open thrombectomy compared to
anticoagulation alone.3 Early lysis or thrombectomy has
been proposed as an attractive option in the treatment of
DVT as this might prevent venous obstruction, valvular
incompetence and venous hypertension from developing.3
This in turn might reduce the incidence or severity of PTS
and reduce the incidence of subsequent venous ulceration.3
However, this hypothesis of early clot removal in acute
DVT has not been conclusively proven. A number of multi-
centre randomised controlled trials are currently underway
to investigate the effectiveness of catheter-directed
thrombolysis (CDT) in the management of DVT. Other
techniques to reduce the clot burden are surgical throm-
bectomy that exposes patients to anaesthetic, procedural
and infective risks.3 or percutaneous mechanical throm-
bectomy (PMT). PMT devices offer an appealing, endove-
nous solution for aggressive thrombus removal and may beused as an adjunct to, or in place of, CDT. PMT may
attenuate the morbidity of CDT by permitting a dose
reduction in thrombolytic drug administration. A number of
devices exist and the emerging data have not been subject
to critical analysis. The aim of this review was to appraise
the growing evidence base for PMT in the treatment of CDT.
Methods
The objective of this article was to review the case selec-
tion, technical aspects, safety outcomes and procedural
outcomes reported after PMT in patients with DVT. An
electronic search was performed using the Embase and
Medline databases. The free-text search terms “thrombol-
ysis”, “thrombectomy”, “DVT” and “percutaneous” and
MeSH headings “Surgical Procedures, Minimally Invasive”[-
MeSH], “Thrombectomy/*methods” [MeSH], “Thrombolytic
Therapy/)methods”[MeSH] and “Venous Thrombosis/)
therapy”[MeSH] were used in combination with the Boolean
operators AND or OR. The reference lists of articles
obtained were also searched to identify further relevant
citations. Finally, the search included the Current
Controlled Trials Register (www.controlled-trials.com), the
DARE database and the Cochrane Database of Controlled
Trials.
Studies reporting open surgical thrombectomy rather
than endovenous thrombectomy were excluded.3,12e18 One
study was withdrawn from publication for unstated reasons
and was therefore excluded.19 Data published previously by
the same group were excluded,20 and studies in which data
for PMT were not discernible from data for patients
undergoing CDT without PMT were excluded.21e23
The literature review conformed to PRISMA statement
standards.24,25 Quantitative pooled meta-analysis was not
performed due to the heterogeneity of study design,
treatment methodology and patient population in studies
that were included in qualitative review. Data were
collected regarding case selection (age of thrombus, inci-
dence of PCD, mean age of patients, co-morbidity), tech-
nique (veins treated, access vessel, device used) safety
outcomes (PE, death, stroke and bleeding requiring trans-
fusion) and procedural outcomes (clinical success, tech-
nical success, DVT recurrence, post-thrombotic syndrome,
reduction in the dose of, or need for, thrombolysis).Results and Discussion
The literature search identified 66 articles, of which 50
were excluded (Fig. 1, PRISMA Flowchart). A total of 16
retrospective case series of PMT were analysed, which
reported 511 procedures in 481 patients. 2/16 studies were
retrospective comparative (cohort) studies of PMT along-
side CDT versus CDT alone.20,26,27 There were no published
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Figure 1 PRISMA Flow diagram to illustrate the number of articles retrieved and selected for analysis during the literature review
of percutaneous mechanical thrombectomy for Deep Vein Thrombosis.
556 A. Karthikesalingam et al.randomised controlled trials (RCTs) of PMT (with or without
CDT) compared to standard treatment (anticoagulation
alone). No prospective or population level data were
available. Four ongoing studies were identified, which have
not published their results to date: the PEARL registry
(NCT00778336), the ATTRACT trial28 (NCT00790335), the
CAVA trial (NCT00970619) and the SONIC I Safety and Effi-
cacy study (NCT00640731).
Case selection
Guidelines from the American College of Chest Physicians
(ACCP) suggest that PMT provides greatest benefit in young
and functionally active patients, with extensive and prox-
imal thrombus (IVC and ilio-femoral), who have an acute
presentation of DVT (<14 days, or with phlegmasia caerulea
dolens).29 The mean age of patients selected for PMT in the
literature supported this recommendation and ranged from
43 to 57 years, with few reported co-morbidities (Table 1).
The prevalence of malignancy (8e42%) reflects the pro-
thrombotic nature of the disease, which leads to DVT in 15%
of cancer sufferers,30 although few data are available to
examine the effect of malignancy on success or long-term
benefit after PMT. Despite recommendations that clotremoval is limited to proximal IVC and iliofemoral DVT,29,31
many studies reported a mixed cohort of IVC and proximal
iliofemoral DVT with femoropopliteal DVT, or included arm
DVT in case selection (Table 1). Although the anatomical site
of DVT is important and expert consensus suggests that DVT
behaves differently at different sites,29 the heterogeneity
and poor quality of available data prevented specific analysis
of the effect of DVT location on outcomes from PMT.
Thrombus age appeared to correlate negatively with the
success of lysis and many studies reported poorer clinical
and technical outcomes in patients with thrombi of more
than 10e14 days age32e34 with better outcomes in patients
with acute clots. However, none of the cohort studies was
powered, or designed, to assess the effect of the duration
of DVT on outcome from PMT. It has previously been sug-
gested that thrombolysis for DVT should commence within
10 days of symptoms to ensure optimal venous recanalisa-
tion, preservation of valve function and symptom relief.29
This suggestion was not supported by the results of
a recent randomised controlled trial: the CaVenT study
demonstrated a significant increase in patency at 6 months’
follow-up after CDT for iliofemoral DVT in patients treated
up to 21 days after the onset of symptoms.35 Furthermore,
the ATTRACT trial, which will report on outcomes of
Table 1 Characteristics of studies of Percutaneous Mechanical Thrombectomy (PMT) for Deep Venous Thrombosis (DVT).
Author,
year
No. of
patients
Age
Median
(range) or
mean  s.d.
(years)
Follow-up Co-morbidity %
Phlegmasia
Age of clot Vein treated Access
vessela
Deviceb % Lysis,
technical
and clinical
successc,56
Post-
thrombotic
syndrome
DVT
recurrence
% Needing
concurrent
thrombolysis
or dose
reduction in
thrombolysis
Length
of stay
Gandini,
199950
8 57.4 (24
e75)
3e24
months
25% Hypertension
(2/8)
12.5% Recent
Myocardial
Infarction
(1/8)
12.5% Obesity
(1/8)
12.5% Cerebral
metastasis
(1/8)
12.5%
(1/8)
Clinical
history
<2 weeks
62.5% Unilateral
Iliac Vein
Thrombosis þ IVC
Thrombosis (5/8)
37.5% IVC
Thrombosis (3/8)
Right I
JV
ATD 75% Complete
(6/8)
12.5% Partial
(1/8)
12.5% Failure
(1/8)
12.5%
(1/8)
12.5% (1/8) 0 e
Delomez,
200134
18 37.6 
16/1
29.6
months
16.7% Malignancy
(3/18)
22.2%
Hypercoagulability
(4/18)
22.2% Oral
contraceptive pill
(4/18)
0 45.3 
76.3d
(Excluding
3 old clots
>2 months
11.3 
6.9d)
16.7% Iliofemoral
(3/18)
27.8% IVC (5/18)
55.6% IVC þ Iliac
(10/18)
83.3%
CFV
(15/18)
16.7% PV
(3/18)
ATD 56% (10/18)
symptom
resolution
85% technical
success
5.6%
(1/18)
0 e e
Kasirajan
200157
17 41 
20
8.9  5.3
months
41.2% Malignancy
(7/17)
5.9%
Hypercoagulability
(1/17)
17.6% May-Thurner
(3/17)
0 e 5.9% IVC (1/17)
52.9%
Iliofemoral (9/17)
5.9%
Iliofemoropopliteal
(1/17)
17.6% IVC þ
Iliofemoral (3/17)
17.6% upper limb
(3/17)
CFV
or PV
Angiojet
with UK,
rt-PA or
reteplase
82% technical
and clinical
success
Grade III: 24%
Grade II: 35%
Grade I: 41%
0 49%
recurrence
at 11 months
CDT used
for 9/13
patients
with <90%
thrombolysis
by PMT alone
e
Vedantham,
200232
20 (22
procedures,
28 limbs)
Group A:
(n Z 4)
acute
thrombus
during stent
placement
Group B:
(n Z 9)
PMT before
CDT
Group C:
(n Z 15)
PMT after
CDT
52.6 
16.4
e e e 18% (4/22) 0d
64% (14/22)
<10d
18% (4/22)
>10d from
symptoms to
treatment
57% One leg
treated (16/28)
21% Both legs
treated (6/28)
32% IVC
involved (9/28)
43% Unilateral
Iliofemoral
(12/28)
4% Unilateral
Femoropoliteal
(1/28)
75% PV
(21/28)
11% CFV
(3/28)
3.6% IJV
(1/28),
3.6% PTV
3.6% ATV
3.6% SSV
24 ATD
7 Angiojet
2 Tretorola
1 Oasis
with UK,
rt-PA or
reteplase
Results for
Grp A/B/C:
Grade III lysis:
75%/0%/13%
Grade II lysis:
25%/33%/53%
Grade I lysis:
0%/66%/33%
% Thrombus
removal:
Group A 93.8%
 12.5%
Group B
26%  24.1%
Group C
62%  24.9%
1/28
(4%)
1/28 (4%) Group C
treated with
PMT after
CDT
e
(continued on next page)
Table 1 (continued)
Author,
year
No. of
patients
Age
Median
(range) or
mean  s.d.
(years)
Follow-up Co-morbidity %
Phlegmasia
Age of clot Vein treated Access
vessela
Deviceb % Lysis,
technical
and clinical
successc,56
Post-
thrombotic
syndrome
DVT
recurrence
% Needing
concurrent
thrombolysis
or dose
reduction in
thrombolysis
Length
of stay
Vedantham,
200433
18 (23 limbs) 49.7 
14.4
19.8  11.6
months
11.1% Factor V
Leiden (2/18)
11.1% malignancy
(2/18)
27.8% oral
contraceptive pill
(5/18)
e 78% (14/18)
symptoms
<10d
22% (4/18)
symptoms
>10d
43.5% Unilateral
iliofemoral (10/23)
21.7% IVC þ bilateral
iliofemoral (5/23)
13% IVC þ Unilateral
iliofemoral (3/23)
87% PV
(20/23)
8.7% IJV
(2/23)
4.3% ATV
(1/23)
4.3% PTV
(1/23)
Helix,
Routine
placement
of Wallstent,
reteplase
100% technical
success
96% clinical
success
Grade III:
31% (7/23)
Grade II:
52% (12/23)
Grade I:
17% (4/23)
0 0 Mean
per-procedure
reteplase
dose was
16.8U  8U
e
Lin,
200626
93 (98
procedures)
52 PMT þ
CDT vs.
46 CDT
alone
45  12
(PMT)
49  10
(CDT)
13  6.2
months
PMT vs. CDT:
Malignancy 9/49
(18%)
vs. 6/44 (14%)
Hypercoagulable
state 6/49 (12%)
vs. 8/44 (18%)
May-Thurner
syndrome 10/49
(20%) vs. 9/44
(20%)
Recent operation
5/49 (10%) vs. 3/44
(7%)
Oral contraceptive
4/49 (8%) vs. 6/44
(14%)
7.7%
(4/52)
PMT
10.9%
(5/46)
CDT
From USS
diagnosis to
intervention:
PMT 15d
(0e34)
CDT 13d
(0e31)
100% Iliac or
Iliofemoral
thrombosis
0% solitary
IVC thrombus
100% CFV
or PV
Angiojet
with reteplase,
rt-PA, or UK
Grade III:
75% (39/52)
PMT vs. 70%
(32/46) CDT
(p Z ns)
Grade I/II: 25%
PMT vs. 30%
CDT (p Z ns)
Clinical success
81% PMT vs. 72%
CDT (p Z ns)
e 6/93 (6.5%) e PMT
4.6 
1.3d vs.
CDT
8.4 
2.3 d
(p < 0.02)
Lee,
200652
25 (20
with CDT)
56 (28e
64)
16months
(12e33)
80% May-Thurner
syndrome (20/25)
8% Malignancy (2/25)
4%
(1/25)
100% extensive
iliofemoral
100% PV Trerotola 100% clinical
and technical
success
85% one-year
patency
0 0 20/25
concurrent
thrombolysis
(80%)
e
Arko,
200758
30 50.9 
18
6.2
months
(3e24)
33% (10/30)
hypercoagulable
state
e 5.7d (3e
14d) after USS
diagnosis
47% Iliofemoral
(14/30)
20%
Iliopopliteofemoral
(6/30)
17% femoropopliteal
(5/30)
17% subclavian
(5/30)
83% PV
(25/30)
17% CV
(5/30)
18 Trellis-8
12 Angiojet
17/30
wallstent
100% technical
success
0 0 6.2 mg (5e10)
tenecteplase
with Trellis-8
10 mg with
angiojet
e
Bush,
200459
23 52  6 10.2
months
(3e26)
21.7% Malignancy
(5/23)
17.4% May-Thurner
(4/23)
13% Hypercoagulable
state (3/23)
e 14d (0e34d)
after USS
diagnosis
52% Iliofemoral
(12/23)
48%
Femoropopliteal
(11/23)
100% PV
(23/23)
Angiojet
with UK,
rt-PA or
reteplase
74% Clinical
Success (17/23)
Grade III lysis
65% (15/23)
Grade I/II lysis
35% (8/23)
0 13% (3/23) 100%
concurrent
thrombolysis
reteplase, t-PA
or urokinase
e
Cynamon,
200660
24 43 (16e
86)
5.3 months
(minimum
1 month)
e 12.5%
(3/24)
83% (20/24)
symptoms
<14d
17% (4/24)
>14d
62.5% (15/24)
unilateral Iliac
þ IVC
37.5% (9/24)
Iliofemoropopliteal
CFV or
PV
Angiojet,
rt-PA,
urokinase
Grade III 50%
(12/24)
Grade II or I 50%
(12/24)
0 8.3% (2/24) 33.3% (8/24)
required CDT
e
Gasparis,
200961
14 40 (19e
58)
24 months
(13e69)
21%
hypercoagulable
(3/14)
86% (12/14)
symptoms
<14d
(median 5d,
range
2e14)
14% > 14d
(median 18d,
range 15e21)
93%
Femoropopliteal
(1/14)
7%
Iliofemoropopliteal
(13/14)
PV Angiojet,
urokinase
Grade III lysis 64%
(9/14)
Grade II or I lysis
36% (5/14)
100% technical
success
86% clinical
success (12/14)
0 7% (1/14) 57% required
CDT (8/14)
e
Jackson,
200562
28 (21
thrombectomy)
Range 22e
80
Mean 15.5
months
e e 72% symptoms
<14d, 18% >
14d
43% iliofemoral,
57% infrainguinal
PV ATD
(Urokinase,
retevase,
rt-PA)
28.5% (6/21)
>90% thrombus
removal
19% (4/21)
60e90% thrombus
removal
52.4% (11/21)
<60% thrombus
removal
0 0 21/28 CDT þ
PMT
7/28 CDT alone
e
Kim,
200620,27
67 limbs
(57 patients)
27/67 PMT
þ CDT
40/67 CDT
alone
PMT 43.1
 13.8
CDT 45
 16.3
e PMT/CDT:
Cancer 28%/59%
Thrombophilia
18%/7%
e Symptoms
<14d
PMT/CDT:
30%/35%
Brachiosubclavian
70%/65%
Iliofemoral
PV
or BV
Angiojet,
Urokinase
PMT/CDT
Grade III
81%/73%
p Z 0.395
Grade II
19%/15%
p Z 0.704
Grade I
0%/13%
p Z 0.056
0 0 Significant
reduction in
urokinase dose
with PMT
p Z 0.008
(2.7  1.8 vs.
5.6  5.3
million units)
e
Rao,
200951
43 48.4 
16.6
5  4.8
months
19% malignancy
(8/43)
35%
hypercoagulable
(15/43)
9.3%
(4/43)
Symptom
duration
13.6  9.6d
44% > 14d
35 lower limb
(8/35 IVC
involvement)
8 upper limb
77% PV,
14% BV,
7% IJV,
2% SSV
Angiojet
(12)
Trellis-8
(13)
Both (17)
With rt-PA
91% > 50%
lysis
0 0 37% underwent
CDT after PMT
due to
incomplete
lysis with PMT
e
Shi,
200963
16 (18 limbs) 53.3 
15.6
e 18.8% Malignancy
(3/16)
25%
Hypercoagulability
(4/16)
e 4.9  3.9d Iliofemoropopliteal
14/16
IVC þ
IliofemoropoplIiteal
2/16
PV ATD (10/16)
Straub
(6/16) with
UK
55.5%
Grade III
(10/18)
33%
Grade II
(6/18)
11%
Grade I
(2/18)
75% clinical
success
(12/16)
1/18 (5.6%) 1/18 (5.6%) 100% received
concurrent
urokinase
7  2.5 d
(continued on next page)
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l.combined PMT and CDT in the United States, has used 14
days as the cut-off for recruitment.28 However, the dura-
tion of symptoms is known to be a poor measure of
thrombus volume and characteristics.36 Furthermore,
thrombus itself may be heterogeneous, with older and
fresher components. Although the ATTRACT trial will add to
consideration of optimal timing for intervention in the
setting of acute proximal thrombosis based on symptom
duration, the effect of thrombus heterogeneity and actual
thrombus age may be difficult to elucidate.
Device selection and technical considerations
PMT devices are categorised as rotational, rheolytic, or
ultrasound-enhanced and were most commonly inserted
into the ipsilateral popliteal vein (Table 1), although
a variety of access vessels have been reported successfully
including the posterior tibial vein.
Rotational devices, such as the Amplatz Thrombectomy
Device (ATD, or Helix, Amplatz Thrombectomy Device
(ATD); Microvena, White Bear Lake, Minneapolis, USA),
Straub Rotarex (Straub Medical, Wangs, Switzerland) and
the Tretorotola Device (Trerotola Percutaneous Throm-
bectomy Device; Arrow International, Reading, Phila-
delphia, USA) employ a high-velocity rotating helix or
nitinol cage to macerate thrombus. The Trellis device
(Trellis-8; Bacchus Vascular, Santa Clara, California, USA)
employs a sinusoidal nitinol wire to disintegrate thrombus
infused with thrombolytic agent between proximal and
distal balloons for control and to prevent PE. This category
of PMT device has the potential for endothelial damage,
though no comparative studies have been performed to
analyse whether this translates to a higher risk of recurrent
thrombosis in clinical practice compared to rheolytic
devices.
The Angiojet device (Angiojet; Possis, Minneapolis, USA)
uses a rheolytic mode of action. The “Power Pulse” tech-
nique is used to spray the thrombus with thrombolytic drug.
The device then generates a high-pressure saline jet to
create a pressure gradient, resulting in rheolytic throm-
bectomy with aspiration of the softened thrombus into the
catheter, where it is fragmented by the saline jets. A
possible advantage of the Angiojet device is that there is no
contact of a rotational component with the vessel wall.
However, its use of high-pressure saline jets carries
a theoretical risk of haemolysis and the release of adeno-
sine and potassium.37 This has been linked to the incidence
of bradyarrhythmia in cardiac applications of the device,38
or haemoglobinuria.39 Presentation of the mid-term results
of the PEARL registry revealed that 1/332 patients experi-
enced a serious adverse bradycardic episode, which was
classified as “possibly related” to the use of the Angiojet
system by the investigating physician.40 To lessen the risk of
haemolysis, a shorter duration of action has been recom-
mended; some authors advise multiple shorter activations
with each pass limited to 5 s41 Isolated reported of
secondary pancreatitis and renal failure further caution
against prolonged device use.42e44
Ultrasound-enhanced devices, such as the EKOS Endow-
ave (EKOS Corporation, Bothell, WA, USA) and Omniwave
(Omnisonics Medical Technologies, Wilmington, MA, USA)
Systematic Review of Percutaneous Mechanical Thrombectomy 561utilise catheters containing multiple ultrasound trans-
ducers, which radially emit high-frequency, low-energy
ultrasound energy. The ultrasonic energy expands and thins
the fibrin component of thrombus, exposing plasminogen
receptor sites, which enhances the transport of thrombo-
lytic agents within target thrombus.45 Although this tech-
nique may be associated with fewer haemolytic effects
than rheolytic thrombectomy46 and has a lower potential
for endothelial damage than rotational thrombectomy
devices, the omission of a mechanical mode of action may
lead to longer thrombolytic infusion times.
The importance of PMT device selection requires
focussed investigation to determine any contribution of
differences in endothelial damage on DVT recurrence, of
differences in haemolysis on cardiac side-effects and
of differences in mechanism on the extent to which
thrombolytic times can be minimised. The benefit of
various devices used alone or in combination, for differing
thrombus characteristics and clinical scenarios, requires
considerable clarification.
Procedural outcomes
Early procedural outcomes were encouraging and the series
reviewed reported technical success of 82e100% (Table 1),
demonstrating the feasibility of PMT. The early clinical
success of CDT or PMT has been quantified by a 3-tiered
grade to reflect postoperative luminal patency. Grades II or
III represent a satisfactory therapeutic outcome of at least
50% luminal patency post-lysis,47 because this value has
been shown to correlate with significantly improved 1-year
patency.47 Grade II or III patency was reported in 83e100%
of patients who underwent the combined use of PMT with
CDT. This provides encouraging evidence for PMT, although
there was significant heterogeneity in the methodology
used to report thrombus lysis by different studies (Table 1).Table 2 Mid-term outcomes from PMT.
Author, year Clinical follow-up
Gandini, 199950 75% (6/8) symptom free at 24 months
Delomez, 200134 93% (14/15) symptom free at mean 29.6 months
3/18 lost to follow-up: died from MI or cancer
(unrelated to PMT)
Kasirajan, 200157 51.8% Recurrence-free survival at 11 months
Vedantham, 200232 e
Vedantham, 200433 89% (16/18) symptom free or mild symptoms
only at mean 19.8  11.6 months
5/23 limbs (3/18 patients) lost to follow-up
Lin, 200626 e
Lee, 200652 92% 1-year clinical success
Arko, 200758 e
Bush, 200459 82% reported symptom improvement at 10.2  0.3
Cynamon, 200660 90% (19/21) symptom-free at mean 5.3 months
3/24 lost to follow-up
Gasparis, 200961 93% (13/14) symptom-free or mild symptoms only a
median 24 months (range 13e69)
Jackson, 200562 e
Kim, 200620,27 e
Rao, 200951 98% complete symptom resolution or significant
symptom improvement at 5  4.8 month follow-up
Shi, 200963 e
Parikh, 200855 eAn important drawback of phlebographic patency as an
indicator of procedural success is that this scale does not
account reliably for the potential effect of residual
thrombus load; the associated partial luminal obstruction
which is difficult for physicians to quantify.48 Intravascular
ultrasound allows the detection of residual stenosis and
external compression after treatment of DVT, yet was not
reported in the series reviewed. Furthermore, data to
report clinical outcome, using validated systems such as the
Villalta score,49 or quality of life, are lacking. Further
evidence is required to ascertain the effects of PMT on
these important clinical outcomes.
Early studies reported the use of PMTwithout adjunctive
CDT34,50 and two later studies noted successful lysis in the
subgroup of patients treated solely with PMT due to contra-
indications to thrombolysis.51,52 Both Rao et al and Lee et al
acknowledged that administering CDT alongside PMT was
preferable to PMT alone as it facilitated thrombectomy.
Significant improvements in thrombus removal have been
demonstrated using CDT in combination with PMT compared
to the use of PMT alone (62.4%  24.9 vs. 26%  24.1,
p Z 0.006),21 and there is consensus that CDT should be
utilised alongside PMT unless there is a specific contraindi-
cation to thrombolysis or anticoagulation.53,54 Ultrasound-
enhanced devices such as the EKOS Endowave (EKOS Corpo-
ration, Bothell, WA, USA) require obligatory adjunctive CDT
due to their mode of action, which improves penetration of
thrombolytic drugs but does not mechanically remove
thrombus. Suchdevices are associatedwith longer treatment
times than mechanical PMT devices, with a median of 22 h
reported.55 Iliac vein stenting was performed adjunctively
according to individual clinical judgement in the reported
studies, with no specific criteria outlined for the use of stents
in any of the analysed studies (Table 1). This methodological
heterogeneity represented a potential confounding factor in
analysis of PMT devices. Future studies must record bothRadiological follow-up
75% (6/8) negative CT venogram at 24 months
93% (14/15) negative duplex ultrasound (USS) at 6 months
77% (13/17) USS patency at 8.9  5.3 months
e
e
68% primary patency at 1 year in PMT cohort
64% primary patency at 1 year in CDT cohort
85% 1-year patency (CT venography)
90% patent ultrasound (USS) at mean 6.2 months
(range 3e24)
months e
e
t 74% free from USS evidence of segmental reflux at
median 24 months (range 13e69)
80% long-term USS patency at mean 15.5 months
e
95% KaplaneMeier freedom from DVT recurrence or
re-intervention at 9 months
75% venous patency at 13 months
e
562 A. Karthikesalingam et al.indications for stenting, stent use and long-term follow-up
after stent placement.
Many studies reported mid-term follow-up, with
encouraging clinical and radiological results (Table 2).
75e98% of patients demonstrated significant mid-term
improvement in symptoms with similar radiological find-
ings, although loss to follow-up was a disadvantage of the
retrospective nature of the existing evidence for PMT.
Safety outcomes
The different devices all appeared to be safe, with no
reported procedure-related deaths or strokes, and <1%
incidence of symptomatic PE (Table 3). 10/16 studies
reported the use of prophylactic IVC filters, although indi-
cations for their use were diverse due to the retrospective
nature of the evidence base (Table 3). The majority of
studies reported no major bleeding complications, though
6/16 studies reported the need for transfusion in 4.2%e14%
of 130 patients. However, these data should be interpreted
with caution as all studies to date report retrospective data
in highly selected groups of patients, with small sampleTable 3 Safety outcomes of PMT.
Author, year PE Death Use
Gandini, 199950 0 12.5% (1/8) from MI
(unrelated to PMT)
Yes
6/8t
2/8
Delomez, 200134 0 16.7% (3/18) from cancer
or MI (unrelated to PMT)
Yes
16/1
2/18
Kasirajan, 200157 0 17.6% (3/17) from cancer
unrelated to PMT
No
Vedantham, 200232 0 0 No
Vedantham, 200433 0 11% (2/18) e
unrelated to PMT
No
Lin, 200626 0 0 Yes
28/5
15/5
Lee, 200652 0 0 Yes
Selec
cont
adju
Arko, 200758 5/30 (17%) detectable on
CT only. None
symptomatic.
0 Yes
21/2
Bush, 200459 0 0 Yes
4/23
3/23
Cynamon, 200660 0 0 Yes
19/2
Gasparis, 200961 0 0 Yes
Tem
free-
Jackson, 200562 0 0 No
Kim, 200620,27 PMT/CDT 4%/3%,
p Z 0.818
0 e
Rao, 200951 0 0 Yes
16 h
perm
Tem
PMT
Shi, 200963 0 1/18 (unrelated death
due to malignancy)
Yes
Tem
Parikh, 200855 0 0 esizes. Selective reporting cannot be discounted and
a degree of publication bias should therefore be assumed.
It has been suggested that procedure-related mortality is
a poor choice of outcome measure for evaluation of CDT or
PMT and that a greater focus on patient-related outcome
measures, including quality of life analysis, would be
beneficial.31 There was significant methodological hetero-
geneity between the studies (Table 1), with a variety of
PMT devices and a range of adjunctive thrombolytic drugs
employed. Future research should provide methodological
standards to enable comparison of results between
different centres.
Comparative evidence for PMT versus CDT
The development of endovascular technology focussed
attention on less invasive ways of removing the thrombus
load in DVT, principally catheter-directed thrombolysis
(CDT).31 Younger patients with acute onset of extensive,
proximal (ilio-femoral) DVT, who may have underlying
anatomical abnormalities or acute limb compromise,
appeared most likely to derive benefit.31 Disadvantages ofof prophylactic IVC filter Stroke Bleeding complication
requiring transfusion
emporary filter
permanent filter
0 0
8 temporary filter
permanent filter
0 0
0 0
0 3/22 (14%)
0 1/18 (6%)
2 temporary filter
2 permanent filter
0 Decreased blood transfusion
requirement in PMT group vs CDT
group (0.2 units vs 1.2 units,
p < 0.05)
tive in 4/25 with
raindication to
nctive CDT
0 0
5 temporary filter
0 0
temporary filter
permanent filter
0 0
4 temporary filter
0 0
porary in 6/23 with
floating IVC thrombus
0 0
0 0
0 PMT/CDT 5.3%/7.7%, p Z 0.749
ad pre-existing
anent filter
porary filter used before
if caval involvement.
0 4/43 (9.3%) required transfusion
porary IVC filters in all patients
0 0
0 2/47 (4.2%) required transfusion
Systematic Review of Percutaneous Mechanical Thrombectomy 563CDT have precluded its universal implementation but may
be ameliorated by adjunctive PMT; these include medical
contraindications to thrombolysis, the risk of bleeding
complications in up to 11%, long infusion times (on average
53.4 h) and significant economic cost incurred by the need
for close monitoring during treatment.47 Two retrospective
cohort studies reported comparative analysis of rheolytic
PMT with CDT in 150 patients (165 limbs), providing
convincing evidence in favour of rheolytic PMT with the
Angiojet device as an adjunct to CDT. Lin et al26 found no
difference in thrombus clearance, but identified that PMT
using the Angiojet device for rheolytic thrombectomy was
associated with a significantly shorter length of stay in ITU
(0.6 days vs. 2.4 days, p < 0.04) and hospital (4.6 days vs.
8.4 days, p < 0.02). There was a significantly shorter
treatment time for PMT (mean 76 min) than CDT (mean
18 h), and a lower requirement for interval venograms (0.4
vs. 2.5, p < 0.001) with the ensuing benefits of lower
radiation dose, nephrotoxicity and cost.
This resulted in significant savings in the total hospital
cost of PMT compared to CDT, which was calculated from
the sum of the operating room, radiological and hospital
room costs ($47,742  $19,247 per PMT patient vs.
$85,301  $24,832 per CDT patient, p < 0.01). These
findings were in accordance with those of Kim et al,20,27
who reported the clinical and economic findings of a retro-
spective institutional series using the Angiojet device for
rheolytic thrombectomy. They demonstrated a significant
reduction in treatment duration with PMT (26.3  16.6 h vs.
48  27.1 h, p Z 0.0004) and in urokinase dose (2.7  1.8
million units vs. 5.6  5.3 million units, p Z 0.008).27 In
a separate economic analysis of patients treated during the
same time period, the mean urokinase and equipment cost
per patient was cheaper for PMT than CDT ($5128 vs.
$10,127, p Z 0.026).
It should be noted that other healthcare services, such
as the English National Health Service, operate through
a tariff costing system, in which admissions are reimbursed
according to a set tariff making the device costs critical.
These differ widely; for example the Angiojet Ultra Console
costs £31500 with disposable catheters at £850 to £1250
each (personal communication, MedRad Ltd., Cambridge,
United Kingdom), the Trellis-8 device retails at £1250 in the
UK (Personal communication, Covidien, Hamps., UK) and
the Trerotola Device costs £414 to £572 each (personal
communication, Teleflex Medical, Bucks., UK). Focussed
health economic analysis is required to analyse the fiscal
impact of the array of PMT devices used alone or in
combination in the UK, including the identification of which
patients would derive greatest benefit.Conclusion
Deep vein thrombosis is a common condition with a signifi-
cant socioeconomic burden, particularly in the setting of
PTS and ulceration. The current standard of treatment
remains anticoagulation in the absence of trial data. PMT is
an emerging technology that offers promising results as an
adjunct to CDT. Early reports suggest that PMT is safe and
may be cost-effective with an acceptable safety profile and
encouraging mid-term results.However, the quality of evidence is poor and major RCTs
reporting to consensus standards are needed in tandem
with registry data to prove the safety, efficacy and
compatibility of these devices. These must be combined
with formal cost effectiveness analyses. Until these data
are available there is little substantial evidence to support
the routine use of PMT over CDT alone.Acknowledgements
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